A review of cancer immunotherapy toxicity

By L. B. Kennedy, A. Salama. Ca, 2020

1,176 citations recorded by the source corpus.

Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy, manipulate the immune system to recognize and attack cancer cells. These therapies have the potential to induce durable responses in multiple solid and hematologic malignancies and thus have transformed treatment algorithms for numerous tumor types. Cancer immunotherapies lead to unique toxicity profiles distinct from the toxicities of other cancer therapies, depending on their mechanism of action. These toxicities often require specific management, which can include steroids and immune‐modulating therapy and for which consensus guidelines have been published. This review will focus on the toxicities of checkpoint inhibitors and chimeric antigen receptor T cells, including pathophysiology, diagnosis, and management.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/de7abf89e520074659fb0c98e15db55d48bddb66

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Sailan Zou
2. Wei Huang
3. Qiyu Tong
4. Bowen Liu
5. Yan Tian
6. Xianghui Fu

Citations in the corpus

• Targeting STAT3 in Cancer Immunotherapy (2020, background): “including limited clinical response rates and significant autoimmune-related side effects [3, 153].”